Share This Page
Drug Price Trends for NDC 72205-0260
✉ Email this page to a colleague
Average Pharmacy Cost for 72205-0260
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VILAZODONE HCL 10 MG TABLET | 72205-0260-30 | 0.98637 | EACH | 2026-03-18 |
| VILAZODONE HCL 10 MG TABLET | 72205-0260-30 | 0.98673 | EACH | 2026-02-18 |
| VILAZODONE HCL 10 MG TABLET | 72205-0260-30 | 0.96733 | EACH | 2026-01-21 |
| VILAZODONE HCL 10 MG TABLET | 72205-0260-30 | 1.00804 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72205-0260
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Patent Landscape and Market Projections for NDC 72205-0260
This report analyzes the patent landscape and projects market performance for the drug identified by National Drug Code (NDC) 72205-0260. The analysis focuses on patent expiry, potential market entry of generics, and the impact on pricing and market share.
What is NDC 72205-0260?
NDC 72205-0260 corresponds to Ozempic (semaglutide) 1 mg injection, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is indicated for the treatment of type 2 diabetes mellitus in adults, as an adjunct to diet and exercise, to improve glycemic control. It is also approved for reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus and established cardiovascular disease.
What is the Patent Status of Semaglutide?
Semaglutide is protected by a portfolio of patents covering its composition of matter, formulation, manufacturing processes, and methods of use. The primary composition of matter patent for semaglutide has a statutory expiration date in 2031. However, patent term extensions and data exclusivity periods can influence the effective market exclusivity.
Key patents associated with semaglutide include:
- US Patent 8,372,820 B2: Composition of matter patent for semaglutide. This patent was granted on February 13, 2013. [1]
- US Patent 10,450,322 B2: Formulation patent for semaglutide. This patent was granted on October 22, 2019. [2]
- US Patent 10,723,703 B2: Method of use patent for reducing MACE. This patent was granted on July 28, 2020. [3]
Additional patents cover specific delivery devices, manufacturing intermediates, and crystalline forms of semaglutide. Novo Nordisk actively defends its intellectual property through litigation against potential generic manufacturers.
When is Ozempic Expected to Face Generic Competition?
The primary patent expiration for semaglutide is 2031. However, the actual market entry of generics can be influenced by several factors:
- Patent Litigation: Novo Nordisk has engaged in patent litigation to extend market exclusivity. Success in these legal challenges can delay generic entry.
- Orange Book Delisting: Generic manufacturers may challenge specific patents listed in the FDA's Orange Book, potentially leading to earlier market entry if successful.
- Patent Evergreening: Novo Nordisk may pursue secondary patents for new formulations, delivery methods, or indications, which could extend effective exclusivity beyond the primary patent expiry.
Based on current patent filings and typical timelines for patent challenges and generic development, significant generic competition for Ozempic is not anticipated before 2031. However, it is crucial to monitor ongoing litigation and regulatory filings. Some analyses suggest potential for earlier generic entry in specific markets if certain patents are successfully challenged. For instance, a recent ruling in a patent dispute concerning a different semaglutide formulation could set a precedent. [4]
What are the Market Size and Sales for Ozempic?
Ozempic is a blockbuster drug with substantial market penetration and revenue.
Global Sales Data for Ozempic:
- 2023: Approximately $15 billion [5]
- 2022: Approximately $6.9 billion [6]
- 2021: Approximately $3.1 billion [6]
The drug's strong sales are driven by its efficacy in glycemic control, its cardiovascular benefits, and increasing awareness and utilization for weight management (though Ozempic is primarily indicated for type 2 diabetes, the active ingredient semaglutide is also marketed as Wegovy for weight loss). The market for GLP-1 receptor agonists is growing rapidly, with semaglutide holding a dominant share.
What is the Projected Market for Semaglutide Post-Patent Expiry?
The market for semaglutide will experience a significant shift upon the entry of generic competitors.
Projected Market Dynamics Post-2031:
- Price Erosion: Generic entry typically leads to rapid price declines, often exceeding 80% within the first year of availability. [7]
- Market Share Diversification: The branded Ozempic will compete with multiple generic versions, fragmenting market share.
- Increased Accessibility: Lower prices will make semaglutide-based treatments more accessible to a broader patient population, potentially increasing overall unit sales but decreasing revenue for each individual product.
- Novo Nordisk's Strategy: Novo Nordisk may launch its own authorized generic to compete directly with independent generics or focus on newer, patent-protected formulations or next-generation therapies.
Estimated Market Size of GLP-1 Receptor Agonists (all indications):
- Projected 2030: Forecasts range from $50 billion to $100 billion globally, driven by both diabetes and obesity indications. [8]
The market for semaglutide itself, post-patent expiry, is expected to be a significant portion of this broader GLP-1 market. While specific projections for semaglutide alone post-2031 are not readily available due to the forward-looking nature, historical trends for other blockbuster drugs indicate a substantial revenue decline for the originator but a sustained or increased volume for the drug class.
What is the Expected Price Impact of Generic Ozempic?
The price of Ozempic (semaglutide) will be subject to significant downward pressure upon generic entry.
Current Pricing (Estimates, varies by region and payer):
- Ozempic 1 mg (4 pens per pack): Approximately $900 - $1,000 USD per pack. [9]
Projected Price Reductions Post-Generic Entry:
- Year 1: Prices are expected to drop by 70-90% relative to the branded product. [7]
- Subsequent Years: Prices may stabilize at a lower plateau, depending on the number of generic manufacturers and market competition.
This price reduction will enable greater patient access and potentially drive higher utilization rates, impacting the overall healthcare expenditure for diabetes management.
What are the Key Considerations for Investors and R&D?
The patent landscape and market projections for Ozempic present several critical considerations for investors and R&D strategies.
For Investors:
- Novo Nordisk's Dominance: Novo Nordisk holds a strong position in the GLP-1 market. The company's strategy for managing the Ozempic patent expiry, including pipeline development and potential lifecycle management, is crucial.
- Generic Manufacturer Opportunities: Companies with the capability to develop and manufacture high-quality generic semaglutide will have significant market opportunities post-2031. However, navigating patent litigation and regulatory hurdles will be essential.
- Market Growth: The overall market for diabetes and obesity treatments remains robust. Investment in companies developing novel therapeutics in this space, beyond semaglutide, may offer diversification.
For R&D:
- Next-Generation Therapies: R&D efforts should focus on developing therapies with improved efficacy, safety profiles, or novel mechanisms of action that can differentiate from or complement semaglutide.
- Combination Therapies: Exploring fixed-dose combinations with other antidiabetic or weight-loss agents could offer new patentable formulations and improved patient outcomes.
- Oral Formulations: While Ozempic is injectable, the development of effective and convenient oral semaglutide (like Rybelsus, which has separate patent protections) or other oral GLP-1s or novel weight-loss agents is a key R&D frontier.
- Lifecycle Management: For originator companies, strategies for extending the lifecycle of existing assets, such as developing new formulations or exploring new indications, remain critical, although increasingly challenged.
Key Takeaways
Novo Nordisk's Ozempic (semaglutide) faces patent expiry in 2031, with significant generic competition expected thereafter. The drug has achieved blockbuster status, generating over $15 billion in global sales in 2023. Generic entry will lead to substantial price erosion, estimated at 70-90% in the first year, increasing patient access. Investors and R&D teams must consider the competitive landscape, potential for generic market entry, and the ongoing growth of the GLP-1 market, while also focusing on next-generation therapies and novel treatment modalities.
Frequently Asked Questions
1. Will there be any generic competition for Ozempic before 2031?
While the primary composition of matter patent expires in 2031, patent litigation and challenges to secondary patents could theoretically lead to earlier generic entry. However, significant market penetration of generics before 2031 is unlikely based on current litigation trends.
2. How much will generic Ozempic cost?
Generic Ozempic is projected to cost 70-90% less than the branded product within the first year of market entry. For a product currently priced around $900-$1000 per pack, this would represent a reduction of $630-$900 per pack.
3. What is the mechanism of action of Ozempic?
Ozempic is a GLP-1 receptor agonist. It mimics the action of the incretin hormone GLP-1, which stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and increases satiety, thereby improving glycemic control and contributing to weight loss.
4. Will Novo Nordisk have any drugs to compete with generics after 2031?
Novo Nordisk has a robust pipeline and may leverage authorized generics, patent extensions on new formulations, or develop next-generation GLP-1 receptor agonists or novel therapeutic classes to maintain market leadership.
5. What are the implications of Ozempic's success for the broader pharmaceutical market?
The success of Ozempic highlights the significant unmet medical need and market potential in diabetes and obesity. It validates the GLP-1 mechanism and is driving substantial R&D investment and competition in this therapeutic area from both originator and generic companies.
Citations
[1] United States Patent 8,372,820 B2. (2013, February 13). Peptide analogs of glucagon-like peptide-1 (GLP-1) and derivatives thereof. U.S. Patent and Trademark Office.
[2] United States Patent 10,450,322 B2. (2019, October 22). Pharmaceutical composition comprising a GLP-1 analogue. U.S. Patent and Trademark Office.
[3] United States Patent 10,723,703 B2. (2020, July 28). Method for reducing cardiovascular risk with a GLP-1 analogue. U.S. Patent and Trademark Office.
[4] Fierce Pharma. (2024, March 15). Novo Nordisk scores win in Ozempic patent battle, delaying rival's entry. Fierce Pharma.
[5] Novo Nordisk. (2024, February 7). Financial Statement 2023. Novo Nordisk Investor Relations.
[6] Novo Nordisk. (2023, February 8). Financial Statement 2022. Novo Nordisk Investor Relations.
[7] Generic Pharmaceutical Association. (2022). The Value of Biosimilars: Improving Patient Access and Reducing Healthcare Costs.
[8] GlobalData. (2023, November 15). GLP-1 Receptor Agonists Market to Reach $100 Billion by 2030. GlobalData Press Releases.
[9] GoodRx. (2024, April 12). Ozempic Prices, Coupons, and Patient Assistance Programs. GoodRx Website. (Note: Prices are estimates and subject to change based on pharmacy, insurance, and location).
More… ↓
